OBR Daily Commentary

forumImage

New Guidelines Would Nearly Double Lung Cancer Screenings, Benefit More Women And Black People

(NBC News) July 7, 2020 - New recommendations for lung cancer screening would nearly double the number of Americans eligible for the test, according to guidelines released Tuesday by the U.S. Preventive Services Task Force. The draft guidelines propose lowering the eligibility age for lung cancer screening to 50 from 55, and lowering the number of years a person smoked an average of a pack a day (known as “pack years”) to 20 from 30 to qualify for the test.

Read Article arrow

H. Jack West, MD (Posted: July 08, 2020)

quotesThe benefit of low dose chest CT screening for lung cancer remains somewhat controversial, but this liberalization would allow better detection of patients with lung cancer who fall below the radar for current screening. quotes

Add Comment 1 Comment
forumImage

Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca™ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer

(Jazz) June 15, 2020 - Jazz Pharmaceuticals plc today announced along with its partner PharmaMar that the U.S. Food and Drug Administration (FDA) approved Zepzelca™ (lurbinectedin) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Zepzelca was approved under accelerated approval based on overall response rate (ORR) and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Read Article arrow

H. Jack West, MD (Posted: June 16, 2020)

quotesWe await phase 3 data, but many will welcome a new option with an approximately 35% response rate in phase 2 work to this point. Relapsed small cell lung cancer is a clinical setting in which the FDA-approved standard of care, topotecan, is not widely embraced, due to its significant hematologic toxicity and requirement for 5 days of IV therapy each cycle. The cost of lurbinectedin should lead oncologists to expect to be impressed by phase III data, and many may wait for more data before prescribing it. There is also rather low awareness of lurbinectedin in the broad oncology community and even limited awareness among many thoracic oncologists.quotes

Add Comment 1 Comment
forumImage

FIRE-SCLC Analysis: Largest Ever Study Of First-line Radiosurgery For Brain Metastases From Small Cell Lung Cancer

(UCCC/Colorado Cancer Blogs) June 4, 2020 - The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI). The study represented a substantial research effort including international collaborators from 28 individual centers and one prospective clinical trial from Asia, North America, and Europe.

Read Article arrow

H. Jack West, MD (Posted: June 05, 2020)

quotesThis is a provocative retrospective analysis of outcomes for patients who received stereotactic radiosurgery (SRS) for brain metastasis in the setting of small cell lung cancer compared to whole brain radiation therapy (WBRT), demonstrating numerically superior results with SRS — not statistically significant and potentially explained by selection biases in a retrospective study — but clearly not worse with SRS compared to WBRT. Considering the toxicity concerns with WBRT, I definitely consider SRS to be a very viable option to consider and arguably favor in patients with a limited number of brain metastases from SCLC.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics Professo...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology P...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...